Macquarie Group’s Aprea Therapeutics APRE Stock Holding History

Macquarie Group’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-9	Closed	-$1K	–	2620
2021 Q4	$1K	Hold	9	–	–	﹤0.01%	2592
2021 Q3	$1K	Hold	9	–	–	﹤0.01%	2618
2021 Q2	$1K	Hold	9	–	–	﹤0.01%	2546
2021 Q1	$1K	Sell	9 -5	-36%	-$583	﹤0.01%	2460
2020 Q4	$1K	Hold	14	–	–	﹤0.01%	2350
2020 Q3	$6K	Hold	14	–	–	﹤0.01%	2321
2020 Q2	$10K	Buy	+14	New	+$9.19K	﹤0.01%	2283

Other funds holding APRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Macquarie Group's APRE Position: Q1 2022 in Review

Macquarie Group sold out of Aprea Therapeutics (APRE) in Q1 2022, closing a stake of 9 shares — an estimated $1K sold.

Macquarie Group first reported a position in APRE in Q2 2020 and held it in 7 quarters. The position peaked at $10K in Q2 2020. 40 funds tracked by Wall St. Rank hold APRE as of Q1 2022.

Macquarie Group reported no remaining Aprea Therapeutics position as of Q1 2022 after selling out during the quarter.
Macquarie Group sold 9 Aprea Therapeutics shares in Q1 2022, an estimated $1K.
Macquarie Group first reported a position in Aprea Therapeutics in Q2 2020 and held it in 7 quarters.
Macquarie Group's Aprea Therapeutics position peaked at $10K in Q2 2020.
40 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2022.

Based on Macquarie Group's 13F filing for Q1 2022, filed 16 May 2022.